Tsutomu Masaki

Takamatsu, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 521 publications

Metabolic Burden and Hyperuricemia Are Associated With CKD-Related Outcomes in Individuals With and Without Steatotic Liver Disease.

Metabolic Burden and Hyperuricemia Are Associated With CKD-Related Outcomes in Individuals With and Without Steatotic Liver Disease.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: January 30, 2026

Correction: Morishita et al. MicroRNAs in the Pathogenesis of Hepatocellular Carcinoma: A Review. Cancers 2021, 13, 514.

Correction: Morishita et al. MicroRNAs in the Pathogenesis of Hepatocellular Carcinoma: A Review. Cancers 2021, 13, 514.

Journal: Cancers
Published: September 22, 2025

Chronic Liver Disease Associated Cholangiocarcinoma: Genomic Insights and Precision Therapeutic Strategies.

Chronic Liver Disease Associated Cholangiocarcinoma: Genomic Insights and Precision Therapeutic Strategies.

Journal: Cancers
Published: July 30, 2025

Validation of Liquid Biopsy Using a Methylated SEPT9 Assay and Integrated Index for Detecting Hepatocellular Carcinoma.

Validation of Liquid Biopsy Using a Methylated SEPT9 Assay and Integrated Index for Detecting Hepatocellular Carcinoma.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: July 09, 2025

Antitumor Potential of Epigallocatechin Gallate in Overcoming Molecular Therapy Resistance in Hepatocellular Carcinoma.

Antitumor Potential of Epigallocatechin Gallate in Overcoming Molecular Therapy Resistance in Hepatocellular Carcinoma.

Journal: Anticancer research
Published: June 18, 2025

Antitumor Effects of Epigallocatechin-3-Gallate on Colorectal Cancer: An In Vitro and In Vivo Study.

Antitumor Effects of Epigallocatechin-3-Gallate on Colorectal Cancer: An In Vitro and In Vivo Study.

Journal: Anticancer research
Published: May 29, 2025

The Polyphenol (-)-Epigallocatechin-3-gallate (EGCG) Inhibits the Proliferation of Gastric Cancer Cells and Alters microRNA Signatures.

The Polyphenol (-)-Epigallocatechin-3-gallate (EGCG) Inhibits the Proliferation of Gastric Cancer Cells and Alters microRNA Signatures.

Journal: Anticancer research
Published: May 21, 2025

A Noninvasive Method of Diagnosing Metabolic Dysfunction-Associated Steatohepatitis Using Cytokeratin-18 Fragment and FIB-3 Index.

A Noninvasive Method of Diagnosing Metabolic Dysfunction-Associated Steatohepatitis Using Cytokeratin-18 Fragment and FIB-3 Index.

Journal: Diagnostics (Basel, Switzerland)
Published: February 24, 2025

Prediction of Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease by Type IV Collagen 7S.

Prediction of Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease by Type IV Collagen 7S.

Journal: Gastro hep advances
Published: January 29, 2025

Tips for Hepatologist Referral of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease with Alanine Aminotransferase Levels ≤ 30 U/L.

Tips for Hepatologist Referral of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease with Alanine Aminotransferase Levels ≤ 30 U/L.

Journal: Diagnostics (Basel, Switzerland)
Published: January 27, 2025

Low HDL cholesterol levels in women and hypertriglyceridemia in men: predictors of MASLD onset in individuals without steatosis.

Low HDL cholesterol levels in women and hypertriglyceridemia in men: predictors of MASLD onset in individuals without steatosis.

Journal: Journal of gastroenterology
Published: January 22, 2025

Circulating miR-485-3p as a biomarker for VEGF-associated therapeutic response to atezolizumab plus bevacizumab in hepatocellular carcinoma.

Circulating miR-485-3p as a biomarker for VEGF-associated therapeutic response to atezolizumab plus bevacizumab in hepatocellular carcinoma.

Journal: Journal of gastroenterology
Published: November 04, 2024
Showing 1-12 of 521

Last Updated: 09/26/2026